4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [1][3]. Group 1: Company Overview - 4DMT's lead product candidate, 4D-150, is designed to treat blinding retinal vascular diseases through multi-year sustained delivery of anti-VEGF with a single intravitreal injection, reducing the treatment burden associated with current methods [3]. - The primary indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, while the second indication is diabetic macular edema [3]. - The second product candidate, 4D-710, is the first genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery [3]. Group 2: Upcoming Events - 4D Molecular Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT [2]. - A webcast of the presentation will be available for one year on the company's investor relations website [2].